SAMITOL

SAMITAL(®) (Indena SpA, Milan, Italy) is a new multicomponent and multiacting botanical formulation rationally designed for the relief of oral mucositis induced by chemotherapy and/or radiotherapy in oncological patients. Each of the individual botanical constituents of SAMITAL-standardized extracts of Vaccinium myrtillus, Macleaya cordata and Echinacea angustifolia have a long history of clinical use that corroborates their safety and activity in SAMITAL. A number of pilot trials in oncological patients demonstrated that SAMITAL has good clinical efficacy and tolerability as evidenced by its significant effects in terms of reduction of mucositis, pain and a general improvement in patient quality of life. Importantly, the use of this botanical formulation had the added benefit that patients were able to complete their chemotherapy/radiotherapy regimen. Phase II trials with SAMITAL as part of an overall clinical development program are currently ongoing in Italy and are planned in the USA. <a href="https://www.ncbi.nlm.nih.gov/pubmed/24156331">Source</a>

<a href="http://www.ncbi.nlm.nih.gov/pubmed/23148620" target="_blank">Management of gastrointestinal mucositis due to cancer therapies in pediatric patients: results of a case series with SAMITAL((R)).</a>Future Oncol. Nov 2012;8(11):1481-1486.

<a href="http://www.ncbi.nlm.nih.gov/pubmed/22945882" target="_blank">SAMITAL(R) improves chemo/radiotherapy-induced oral mucositis in patients with head and neck cancer: results of a randomized, placebo-controlled, single-blind Phase II study.</a> Support Care Cancer. Mar 2013;21(3):827-834.

SAMITOL

Attachments